Takeda PharmaceuticalLtd ADR (TAK) - Stock & Dividends

Exchange: USA Stocks • Country: Japan • Currency: USD • Type: Common Stock • ISIN: US8740602052

(NYSE:TAK Stock) Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan. Web URL: https://www.takeda.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Takeda PharmaceuticalLtd ADR (TAK) - Stock & Dividends

TAK Stock Overview

Market Cap in USD 45,677m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2008-10-27

TAK Stock Ratings

Fundamental 1.34
Dividend 5.21
Growth 5y -1.69
Rel. Performance vs Sector -1.51
Analysts 4.20
Fair Price Total Ret. 13.57
Fair Price DCF 2941.69

TAK Dividends

Yield 12m 4.27%
Yield on Cost 5y 4.00%
Dividends CAGR 5y -3.58%
Payout Consistency 91.5%

TAK Growth Ratios

Growth 12m -2.79%
Growth Correlation 12m -53%
Growth Correlation 3m 37%
CAGR 5y -1.27%
CAGR / Mean Drawdown -0.08
Sharpe Ratio 12m -0.45
Alpha vs SP500 12m -20.51
Beta vs SP500 5y weekly 0.58
CAPM 6.83%
Average Daily Range 2m 1.00%
Regime Oscillator 79.56
Volatility GJR Garch 1y 20.74%
Price / SMA 50 2.36%
Price / SMA 200 -1.07%
Current Volume 1454.2k
Average Volume 20d 2049.8k

External Links for TAK Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of TAK stocks?
As of February 22, 2024, the stock is trading at USD 14.74 with a total of 1,454,204 shares traded.
Over the past week, the price has changed by +1.38%, over one month by -0.34%, over three months by +5.14% and over the past year by -3.53%.
Why is TAK stock down?
Check with which Index or Commodity TAK has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return TAK Return S&P 500
1 Month -0.34% 2.85%
3 Months 5.14% 10.14%
12 Months -3.53% 26.48%
What is the forecast for TAK stock price target?
According to ValueRays Forecast Model, TAK Takeda PharmaceuticalLtd ADR will be worth about 14.7 in February 2025. The stock is currently trading at 14.74. This means that the stock has a potential downside of -0.61%.
Issuer Forecast Upside
Wallstreet Target Price 17.1 15.9%
Analysts Target Price 19.1 29.7%
ValueRay Target Price 14.7 -0.6%